Skip to main content

Table 3 MCS and PCS summary scores for DR-TB patients and those enrolled in the comparison groups

From: The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa

 

Mental component summary (MCS)

Physical component summary (PCS)

SF-36 scale$ (Norm-based scale)

Mean

SD

Mean

SD

DR-TB (all patients; n = 149)

38.3

12.9

50.4

9.1

Patient-reported adverse event

 No adverse event

42.2

13.0

52.8

8.2

 Patient-reported adverse event

32.1

9.9

46.5

9.1

HIV status

 HIV negative (n = 27)

41.4

11.6

50.9

8.7

 HIV positive on ART (n = 94)

38.7

12.9

51.2

8.5

 HIV positive not on ART (n = 22)

34.5

13.9

46.7

10.7

 HIV status unknown (n = 6)

32.7

12.5

49.0

11.6

Duration of DR-TB treatment

  ≤ 6 months (n = 66)

31.9

11.3

48.5

9.9

  > 6 months (n = 83)

42.9

12.0

52.6

8.0

DR-TB regimen

 Standard regimen (long- and short-course) (n = 107)

37.9

13.4

51.1

8.9

 Did not report an AE

41.4

13.6

53.2

8.2

 Self-reported AE

31.4

10.4

47.1

8.8

 Individualized regimen (long- and short-course) (n = 42)

39.3

11.6

48.7

9.4

 Did not report an AE

45.1

10.8

51.7

8.3

 Self-reported AE

33.4

9.3

45.6

9.7

Comparison groups

 HIV positive on ART with DS-TB (n = 18)

44.4

15.7

48.5

9.6

 HIV positive on ART no TB (n = 50)

43.3

11.5

54.8

7.3

 Healthy Adultsa (n = 40)

50.3

10.3

57.6

5.1

  1. aFrom published data (van Aswegen et al., 2011)
  2. $Using the 36-Item Medical Outcomes Short Form Health Survey (SF-36)